Participated · Series B · Aug 2026

Mariana Minerals combines proprietary software and capital project execution to build and operate mines and refineries for critical minerals. Its MarianaOS platform integrates CapitalProjectOS, PlantOS and MineOS into a single AI and machine learning stack intended to compress multi-year project execution timelines and reduce commissioning time. The company operates active projects including Copper One, which is ramping toward 50,000 metric tons of refined copper per year, and Lithium One, a GWh-scale facility targeting commercial lithium production from oil & gas produced water in the first half of 2027. Mariana has raised roughly $400 million of parent and project capital to date, including the $310 million Series B. The company plans to scale to 10 commercial-scale projects in 10 years, using data from each project to improve its software and lower costs for subsequent builds.

Participated · Series A · Jul 2026

Turing develops fully autonomous driving technology originating in Japan. The company is scaling its computing infrastructure and commercial operations as it moves toward real-world deployment. In its Series A and extension rounds the company has raised a cumulative ¥27.89 billion (about $174 million), including ¥12.62 billion (about $79 million) in the recent extension. Turing plans to use the new funding to expand compute capacity, strengthen its business organization for deployment, and hire additional staff. The company’s stated goal is to accelerate realization of Japan-developed fully autonomous driving systems.

Participated · Series B · Oct 2025

Rice Parent Co is a Mumbai-headquartered fintech founded in January 2021 by Praveen Yadav, Alok Pandey, J. Prakash Gupta and Runak Rathi. The company’s core offering is a high-speed, reliable stockbroking platform serving Indian retail investors. Its product suite also includes ScanX, which delivers market insights, and two planned financial-education platforms, Upsge and Filter Coffee. Rice Parent Co has trained an AI model on large financial data sets to enhance the information it provides to users. Management credits a product-first culture and strong technology focus for the firm’s rapid, profitable growth in less than four years. After raising a $120 million Series B, the company reached a valuation of about $1.2 billion, giving it fresh capital to expand further into investments, AI and broader financial-services offerings.

Participated · Series A · Mar 2025

Wheeler Bio is a contract development and manufacturing organization (CDMO) built on its Modular CMC scientific platform, focused on accelerating antibody-based therapeutic candidates from discovery into clinical trials. It provides integrated services including manufacturability assessments, stable pool and clone development, process and analytical method development, process demonstration, technology transfer, and cGMP manufacturing. The company emphasizes a customer-intimate approach to build robust CMC packages vital for regulatory filings and ongoing manufacturing. Wheeler plans to broaden capabilities, expand its partner base and team, and is planning a 52,000 square-foot large-scale biologics manufacturing facility adjacent to a biomanufacturing workforce training center at Convergence in the Oklahoma City Innovation District. The company is headquartered in Oklahoma City and cites regional advantages such as lower business costs and a growing biomanufacturing workforce. The recent financing is intended to fund these expansion and capability-build efforts. Wheeler Bio is an Oklahoma City-based contract development and manufacturing organization (CDMO) focused on the gene-to-IND supply chain. Its primary product is Portable CMC, an open-source "CMC middleware" that integrates discovery CROs and CDMOs to streamline translational steps. Portable CMC includes a complement of integrated development services, including manufacturability assessments, stable pool and clone development, process and analytical method development, process demonstration, and technology transfer into CGMP production. The platform also enhances business integrations that speed up translational steps while lowering technical, regulatory, and business risks. Wheeler Bio plans to use the $31M Series A to complete its CGMP cell banking and 500 L drug substance manufacturing facility in The Ziggurat in downtown Oklahoma City. Leadership includes CEO Dr. Jesse McCool, Chief Development Officer Dr. Brian Berquist, and Christian Kanady. Wheeler Bio offers Portable CMC™, a platform that integrates with preclinical discovery to accelerate the discovery-to-IND path. Portable CMC is designed to provide faster, easier, and more predictable tech transfer and clinical supply by partnering with preclinical CROs and antibody drug developers. The company has an initial focus on antibody therapeutics and is partnered with Alloy Therapeutics to extend discovery offerings into IND-enabling manufacturing. Wheeler Bio is headquartered in Oklahoma City and operates pilot labs inside Alloy Therapeutics’ Boston facility. It closed a $14M Seed financing to expand its team and make Portable CMC more broadly available. Scientific and operational leadership for Portable CMC is led by CTO Dr. Stephen Hamilton, and the company emphasizes speed, predictability, and shared success with CDMO and CRO partners.

Participated · Equity · Jan 2025

Mangrove Lithium is commercializing a feedstock-flexible electrochemical refining process that converts various lithium inputs into battery-grade lithium hydroxide or lithium carbonate, aiming to cut costs, carbon intensity, and waste relative to conventional methods. Proceeds from its latest raise will fund commissioning of a 1,000-tonne-per-year "Single Stack Plant" in Delta, British Columbia, expected to supply material for about 25,000 electric vehicles annually. The company is also conducting early engineering and site selection for a full-scale facility with up to 20,000-tonne annual capacity—enough for more than 500,000 EVs. By expanding onshore refining, Mangrove seeks to bolster Western battery-materials supply chains and lessen dependence on overseas processing. Existing strategic and financial backers include Breakthrough Energy Ventures, BMW i Ventures, Mitsubishi Corporation, Asahi Kasei, Orion Industrial Ventures, Export Development Canada, and BDC Capital. The firm’s technology and expansion plans position it at the intersection of cleantech manufacturing incentives and growing lithium demand for EV batteries. No revenue or user metrics were disclosed in the article.